Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C)

Vaccine. 2023 Apr 24;41(17):2743-2748. doi: 10.1016/j.vaccine.2023.03.021. Epub 2023 Mar 15.

Abstract

Understanding the serological responses to COVID-19 vaccination in children with history of MIS-C could inform vaccination recommendations. We prospectively enrolled seven children hospitalized with MIS-C and measured SARS-CoV-2 binding IgG antibodies to spike protein variants longitudinally pre- and post-Pfizer-BioNTech BNT162b2 primary series COVID-19 vaccination. We found that SARS-CoV-2 variant cross-reactive IgG antibodies variably waned following acute MIS-C, but were significantly boosted with vaccination and maintained for up to 3 months. We then compared post-vaccination binding, pseudovirus neutralizing, and functional antibody-dependent cell-mediated cytotoxicity (ADCC) titers to the reference strain (Wuhan-hu-1) and Omicron variant (B.1.1.529) among previously healthy children (n = 16) and children with history of MIS-C (n = 7) or COVID-19 (n = 8). Despite the breadth of binding antibodies elicited by vaccination in all three groups, pseudovirus neutralizing and ADCC titers were significantly reduced to the Omicron variant.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • BNT162 Vaccine*
  • COVID-19 Testing
  • COVID-19 Vaccines
  • COVID-19* / complications
  • COVID-19* / prevention & control
  • Child
  • Humans
  • Immunoglobulin G
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome
  • Vaccination

Substances

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • Antibodies, Viral
  • Immunoglobulin G
  • Antibodies, Neutralizing

Supplementary concepts

  • SARS-CoV-2 variants
  • pediatric multisystem inflammatory disease, COVID-19 related